


Pancreatic Cancer Treatment Market to Surpass \$10.53 Bn by 2032 | SNS Insider

The Pancreatic Cancer Treatment Market, valued at \$2.8 Bn in 2023, is set to grow at a 15.85% CAGR, driven by rising cases & breakthrough therapies.

AUSTIN, TX, UNITED STATES, February 26, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The [Pancreatic Cancer Treatment Market](#) was valued at USD 2.8 billion in 2023 and is projected to reach USD 10.53 billion by 2032, growing at a strong rate of 15.85% during the forecast period.



The market's expansion is fueled by increasing cases of pancreatic cancer, advancements in drug development, and a rising focus on personalized medicine. The demand for innovative treatment options has led to significant investments in research and development, accelerating the adoption of advanced therapies.

Get a Free Sample Report@ <https://www.snsinsider.com/sample-request/2994>

Segmentation Analysis

By Affected Region: Exocrine pancreatic cancer, the most prevalent form of the disease dominated the market with a 63.23% share in 2023.

This segment is poised to continue leading because of the prevalence of exocrine tumors, such as adenocarcinomas, which are the most prevalent form of pancreatic cancer. The growing proportion of late-stage diagnoses and low curative opportunities also add to the segment's large market share.

Conversely, endocrine pancreatic cancer is expected to be the most rapidly growing segment. While less prevalent, endocrine tumors, including pancreatic neuroendocrine tumors (PNETs),

are seeing increasing focus due to advances in early diagnosis and targeted treatments. The better prognosis related to these treatments and heightened clinical research activities are likely to fuel segment growth.

By Type: Targeted therapy emerged as the leading treatment type in 2023, capturing a significant 56.04% share of the market.

This supremacy is due to its effectiveness in inhibiting certain molecules that are responsible for the growth of cancer cells, resulting in improved outcomes and less toxicity than traditional chemotherapy. The expanding use of targeted medicines, including tyrosine kinase inhibitors and monoclonal antibodies, has greatly supported the segment's market share.

Immunotherapy will be the highest-growing segment over the coming years. Emerging progress in cancer vaccines and immune checkpoint inhibitors has shown encouraging data in augmenting the immune system of the body against pancreatic cancers. The active clinical trials and approvals for new immunotherapy treatments are projected to drive significant market growth.

Speak with Our Expert Analyst Today to Gain Deeper Insights @ <https://www.snsinsider.com/request-analyst/2994>

Regional Outlook

North America led the pancreatic cancer treatment market in 2023, accounting for a 40.22% share.

The dominance of this region is driven by its high incidence of pancreatic cancer, established healthcare infrastructure, and intense research activities. The presence of top pharma majors and a strong pipeline of new-age drugs also add to the market leadership of North America.

On the other hand, the Asia-Pacific region is anticipated to experience the highest growth in the coming years. The rising incidence of pancreatic cancer, increasing healthcare expenditure, and enhanced access to sophisticated treatment modalities are major drivers of regional market growth. Furthermore, government efforts to improve cancer care and increased awareness regarding early diagnosis are likely to drive demand for pancreatic cancer treatments in this region.

Key Players in Pancreatic Cancer Treatment Market

- Eli Lilly and Company
- Celgene Corporation
- F. Hoffmann-La Roche AG
- Amgen Inc.
- Novartis AG

- PharmaCyte Biotech Inc.
- Clovis Oncology
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Pfizer Inc

Buy Full Research Report on Pancreatic Cancer Treatment Market 2024-2032 @
<https://www.snsinsider.com/checkout/2994>

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/789331772>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.